Human immunodeficiency virus (HIV) p24 antigenemia was assessed in a longitudinal study of 52 homosexual men who developed serum antibody to HIV. Antibody seroconversion to HIV as defined by a positive HIV enzyme immunoassay (EIA) confirmed by Western (immuno-) blot was associated with three major patterns of HIV antigenemia. In the first pattern, a transient antigenemia was noted 6 (six subjects) and 12 (one subject) months prior to detection of antibody by HIV EIA and Western blot in 7 (13.5%) of the 52 men. Use of an EIA employing a recombinant envelope protein (ENV9) was able to detect antibody in four of these seven men at the time of this early antigenemia. In the second pattern, HIV p24 antigenemia occurred in 8 (15.4%) of the 52 subjects within the first 12 months after HIV antibody seroconversion. No p24 antigen was detected in the 37 (71.1%) remaining subjects. CD4+ cell numbers were lower in antigen-positive men before and after antibody seroconversion. Development of acquired immunodeficiency syndrome (AIDS) or AIDSrelated complex was strongly associated with evidence of persistent p24 antigenemia during the early, postseroconversion period. HIV p24 antigenemia may be of value in determining appropriate cohorts for drug therapy trials for subjects with early-phase HIV infection.
Human immunodeficiency virus (HIV) has been shown to induce the production of circulating antibodies within the first few months of infection (4, 8, 19, 20) . Studies suggest that the development of this host response is associated with a temporal appearance of HIV p24 core antigen detectable in the serum or plasma (2, 9, 13, 18, 21) . This transient antigenemia occurs early in the course of infection and usually precedes antibody production that is detectable by conventional enzyme immunoassay (EIA) or Western (immuno-) blot assay. Of further interest is that asymptomatic or mildly symptomatic HIV antibody-positive subjects with p24 antigenemia have a greater risk for development of acquired immunodeficiency syndrome (AIDS) than do those without antigenemia (1, 5, 7, 14, 16, 17) .
There is little information on the longitudinal pattern of HIV p24 antigenemia after seroconversion to HIV. Such information may be of importance in determining whether the onset of antigenemia after production of antibodies serves as a marker for alterations in immune status Detection of HIV p24 antigen in plasma was done with a commercial kit (HIV p24 Core Antigen ELISA; Du Pont) which utilizes monospecific polyclonal antibody to HIV p24 antigen for capture and detection of antigens in the patient's sample. A positive result is determined by comparison of the absorbance of the patient's sample with the reactive threshold value (0.100 added to the mean of the negative control). The sample must be equal to or greater than the reactive threshold value to be considered reactive. All reactive specimens were confirmed as positive by repeat testing and neutralization of specific signals with human antibodies to HIV (Du Pont); confirmed positive samples showed a reduction in absorbance with the addition of confirmatory reagent of at least 50%. This assay can quantitate 6 pg (0.03 ng/ml) or more of HIV p24 antigen in plasma or serum. In addition, specimens were considered reactive if they had less than 0.03 ng/ml but were greater than the negative control. Of-the 26 antigen-positive specimens, 8 fell within this lower range of reactivity. Seven ofthese eight specimens were confirmed as positive by a second p24 antigen test (Abbott Laboratories, North Chicago, Ill.). One of these eight samples was confirmed positive by one assay (Du Pont) and was negative by the othèr (Abbott) ( Table 1 ; sample T12, subject no. 6).
T-cell phenotyping. The number of T lymphocytes was determined by staining of peripheral blood mononuclear cells with fluorescent-conjugated antibodies to CD3 (Leu 4; Becton Dickinson, Mountain View, Calif.), CD4 (Leu 3a), and CD8 (Leu 2a) by established methods (15 Table 1 ). The antigenemia was present 6 months before the first sample demonstrating HIV antibodies as measured by HIV EIA, which utilizes whole-virus lysate, in five of these seven subjects (subjects 2 to 5 and 7) and at 12 months prior to seroconversion in one study subject (subject 6). In study subject 1, EIA was positive but Western blot was negative by our criteria when p24 antigen was detected. Antibody to HIV was detectable in the HIV EIA-negative samples by ENV9 EIA in three of seven cases as described above. Western blot assay also revealed the presence of envelope (gp41 and gpl60) and core (p55) bands in some of these three HIV EIA-negative samples (see above).
Blood specimens obtained from group 1 men after seroconversion as determined by HIV EIA were negative for p24 antigen except in one of these subjects (subject 6) at one visit ( Table 1) . Levels of antibody to p24 were relatively high after seroconversion in six of these seven men, with Western blot densities of +2 and +3.
Onset or persistence (or both) of HIV p24 antigenemia after HIV antibody conversion. A second pattern of antigenemia was observed in 8 (15.4%) of the 52 men (group 2; Table 2 ). Antigen was detected in five of these eight men by 4 to 12 months after the first HIV-EIA-positive visit (subjects 8, 10, 11, 14, and 15). If one assumes that HIV infection occurred at the midpoint between the last antibody-negative and the first antibody-positive study visits, detection of p24 antigenemia in these five men was a median of 7.5 months after infection. In subjects 9, 12, and 13, p24 antigen was first noted 6 months prior to seroconversion (subject 13) and at the first HIV EIA-positive study visit (subjects 9 and 12). Antigenemia was still evident in most of these men at later study visits. Certain subjects were not evaluable at visits beyond T,6 months due to AIDS illness (subject 8) or failure to complete later study visits (subjects 9 and 14). The levels of HIV antigen did not correlate with time of occurrence or individual study subject (data not shown). Antibody to p24 as determined by Western blot was low (0 and + 1 densities) in four of these eight group 2 men (subjects 10 to 12 and 15).
Absence of detectable HIV p24 antigenemia. In 37 (71.1%) of the 52 men, HIV serum antigen was not detectable before or after onset of antibody production (group 3). All of the 37 men had antibody to p24 by Western blot assay. Of these 37, 5 had low levels (+1) of p24 antibody, whereas the other 32 had antibody densities of +2 and +3.
Relationship of antigenemia with clinical course and T-cell levels. To date, group 1 and group 3 men with early, transient antigenemia or no detectable antigenemia have remained asymptomatic. However, three of the eight group 2 men, who had antigenemia after antibody conversion, developed AIDS (two Pneumocystis carinii pneumonia and one Kaposi's sarcoma) within 13, 29, and 31 months of antibody conversion. These three men died within 6 months of diagnosis of disease, regardless of treatment with zidovudine in all cases. Two of the other eight group 2 men developed AIDS-related complex (ARC) (i.e., weight loss, oral thrush, and lymphadenopathy), whereas the remaining three were asymptomatic. Thus, a strong association was observed between the development of AIDS or ARC in the group 2 men (5 of 8) compared with group 1 men (0 of 7) (P < 0.02, Fisher's exact test). This relationship was more significant if the group 1 and 3 men were combined (0 of 44) and compared with those in group 2 (5 of 8) (P < 0.001). Figure 1 provides the mean + standard error of CD4+ cell counts in groups 1, 2, and 3 at observed time points before and after HIV seroconversion. Reductions in CD4+ lympho- 13, 31 , and 29 months after TO, respectively; subjects 9 and 13 developed ARC by To and 10 months after TO, respectively. b p24Ab (WB), Western blot assay for antibody to p24. ' Western blot gpl20 and gpl60, +2 intensity.
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cytes were observed for all groups during the time of this study. Groups 1 and 2 exhibited reduced mean CD4+ cell numbers before antibody seroconversion and lower mean numbers over time compared with the group 3 men. These differences were significant at 6-month (T+6) and 12-month (T+12) intervals after seroconversion for groups 1 and 2 compared with group 3 (P < 0.05, Duncan's new multiple range test). Similar analysis showed that there was an increase in CD8 cell numbers over time in all three groups of men. The CD8+ cell numbers displayed a temporal, sharp rise at 6 months preconversion in group 1 (P < 0.05 compared with group 2) (Fig. 2) (6, 10) . Monitoring of HIV p24 antigenemia may be of greater importance as an early marker for efficacy of drug therapy in asymptomatic HIV-seropositive men, for whom effects on clinical parameters of infection may require longer-term follow-up.
